JCO || Relapse or persistent ovarian cancer: The remission rate of Navuliyu monoantigen is high

A randomized Phase II trial reported by Zamarin et al. at memorial Sloan Kettering Cancer Center in the United States showed that patients with endotile ovarian cancer (EOC) had a higher rate of remission, a longer (albeit limited) non-progressive lifetime (PFS), and that the combined program was as toxic as previously reported.
other joint studies are needed to confirm the long-lasting efficacy of the double therapy.
(J Clin Oncol. doi: 10.1200/JCO.19.02059.) single-drug PD-1 blockers have limited efficacy in EOC.
the study evaluated the efficacy of the Ipidan anti-combined Narvulyu monoanti-drug Narvulyu monoantigen in women with persistent or relapsed EOC.
group of patients includes measurable diseases, 1 to 3 past treatment options, and non-platinum interstitium (PFI) and 12 months.
participants were randomly assigned 4 doses (once every 2 weeks) or Navuliyu monoantigen induction treatment (once every 3 weeks) to receive intravenous drug Narvulyu monoanti (once every 2 weeks), followed by a maximum of 42 doses of Navuliyu monoantigen maintenance therapy every 2 weeks.
initial invalid assumption is that the objective mitigation rate is equivalent after 6 months of random allocation for each group.
100 patients were assigned to navuliyu monoanti (49 cases) or Navuliyu monoanti (51 cases), and 62% of patients were treated with PFI -lt;6 months.
six months, 6 cases (12.2%) of the Navuliyu monoantigen group and 16 cases (31.4%) of the Navuliyu single resistance group (OR=3.28,85% CI 1.54 to ∞, P=0.034).
the mid-PFS of the Navuliyu single resistance group and the Navuliyu single resistance group were 2 months and 3.9 months, respectively, and the risk ratio of PFI stratifist was 0.53 (95% CI0.34 to 0.82);
33% of patients in the Navuliyu monoantigroup and 49% of patients in the joint group had ≥3-level adverse events and no treatment-related deaths.
in both treatment groups, there was no significant correlation between PD-L1 expression and response.
Her Royal Highness the Queen: Zhang Shi's former public number copyright notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mace Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here